TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).

被引：0
|
作者：
Custodio, J. M. [1 ]
Wei, X. [1 ]
Wang, H. [1 ]
Hepner, M. [1 ]
Zack, J. Z. [1 ]
Callebaut, C. [1 ]
McCallister, S. [1 ]
Miller, M. [1 ]
Kearney, B. P. [1 ]
Ramanathan, S. [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-052
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 50 条
  • [31] A daily single-tablet regimen (STR) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults living with HIV and end-stage renal disease on chronic haemodialysis
    Eron, J. J.
    Wilkin, A.
    Ramgopal, M.
    Osiyemi, O.
    McKellar, M.
    Slim, J.
    Asmuth, D.
    German, P.
    Blair, C.
    Carter, C. C.
    Brainard, D. M.
    Collins, S. E.
    Gohlar, G.
    Martin, H.
    [J]. HIV MEDICINE, 2021, 22 : 24 - 25
  • [32] Strategic simplification: the efficacy and safety of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV) in treatment-experienced HIV-1 infected adults (NCT01968551)
    Huhn, G.
    Gallant, J.
    Wilkin, T.
    Callebaut, C.
    Fordyce, M.
    Das, M.
    Mccallister, S.
    Yau, S.
    [J]. HIV MEDICINE, 2016, 17 : 15 - 15
  • [33] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
    Molina, J-M
    Gallant, J.
    Orkin, C.
    Negredo, E.
    Bhatti, L.
    Gathe, J.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Vanveggel, S.
    Opsomer, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
  • [34] Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to <12 years)
    Cotton, M.
    Liberty, A.
    Rodriguez, C. A.
    Chokephaibulkit, K.
    Kosalaraksa, P.
    Hellstrom, E.
    Natukunda, E.
    Wong, P.
    Majeed, S. R.
    Quirk, E.
    Graham, H.
    Pikora, C.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 38 - 39
  • [35] Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort
    Korten, V.
    Inan, A.
    Akalin, H.
    Gokengin, D.
    Kaya, B.
    Inan, D.
    Ozdemir, H. Ozkan
    Azak, E.
    Dogru, A.
    Dokuzoguz, B.
    Yildirmak, T.
    Kose, S.
    Karaoglan, I.
    [J]. HIV MEDICINE, 2019, 20 : 58 - 58
  • [36] Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in patients with human immunodeficiency virus (HIV)-1 infection: age, race/ethnicity, and gender subgroup analyses from the DIAMOND study
    Anderson, D.
    Bolan, R.
    De Jesus, E.
    Castro, J. G.
    Simonson, R. B.
    Cosler, P.
    Seyedkazemi, S.
    Luo, D.
    Dunn, K.
    [J]. HIV MEDICINE, 2019, 20 : 93 - 94
  • [37] Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial
    Perez Valero, I.
    Cabello, A.
    Ryan, P.
    de la Fuente Moral, S.
    Santos, I.
    Vivancos, M. J.
    Gorgolas, M.
    Cuevas, G.
    Diaz De Santiago, A.
    Garcia-Fraile, L.
    Bernardino, J. I.
    Valencia, E.
    Montes, M.
    Rua, G.
    Yllescas, M.
    Gonzalez, A.
    [J]. HIV MEDICINE, 2019, 20 : 90 - 91
  • [38] High levels of patient satisfaction during rapidly initiated therapy with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) for treatment of HIV-1 infection through 24 weeks of the DIAMOND study
    Benson, C.
    Simonson, R.
    Bicer, C.
    Dunn, K.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [39] Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults
    Orkin, C.
    Molina, J-M
    Gallant, J.
    Negredo, E.
    Gathe, J.
    Eron, J.
    van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Petrovic, R.
    Opsomer, M.
    [J]. HIV MEDICINE, 2018, 19 : S32 - S32
  • [40] Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naive and -experienced, virologically-suppressed adults living with HIV-1
    Huhn, Gregory D.
    Wilkin, Aimee
    Mussini, Cristina
    Spinner, Christoph D.
    Jezorwski, John
    El Ghazi, Mohsine
    Van Landuyt, Erika
    Lathouwers, Erkki
    Brown, Kimberley
    Baugh, Bryan
    [J]. HIV RESEARCH & CLINICAL PRACTICE, 2021, 21 (06) : 151 - 167
12345